EBIT SEK 8.0m (-25%% vs. ABGSCe 10.7m) Sales-mix driven EBIT deviation Trading at 17x ’23e EV/EBIT o...
33% org growth, but 27% EBIT miss due to OEM+VIP+FX 26% EBIT CAGR 2022-2025e on 30% margins 25-15x E...
Redeye updates its estimates for Mestro, a well-positioned property technology company offering a cl...
Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year).
Redeye updates on GiG ahead of its Q4-results (due 15 February) where we expect a strong quarter on ...
Redeye sees a Q4 report that was uneventful as expected.
Redeye updates on EG7 ahead of its Q4-results (due 17 February) where we expect solid performance on...
We expect Stockwik to present a decent Q4 report on 17 February, and forecast EBITA of SEK 26m still...
Prefab struggles, Installation Services better Lowered margin expectations in Products & Solutions 1...
Weaker-than-expected Q4 due to cancelled large customer FY'23 guidance places ABGSCe at the low end ...
Inför Coors Q4-rapport räknar Analysguiden med ökad omsättning och sekventiellt stärkt lönsamhet.
Rekordstarkt 2022, men tecken på avmattning Nettoomsättningen ökade med 22% till 730 mkr i Q4 y/y, v...
Redeye provides an update on Kontigo Care following its Q4 2022 report.
Sales -4%, EBIT -27% vs. ABGSCe, 33% org sales (ABG 49%) Q1 guidance of ~40% growth y-o-y, but negat...
Redeye’s initial comment on the Q4 report was published earlier this morning.
EBIT SEK 66m (-9% vs. ABGSCe SEK 72m) Q4 numbers imply EBIT downgrades of 2% Trading at 12x '23e EV/...
CPI-PPI gap is shrinking - positive for '23e margins Q4'22e sales up 3%, EBITDA down 8% New bolt-ons...
Q4 estimates nearly unchanged We cut '23e-'24e EBIT by 3-2% 8x '23e EV/EBIT What to look for in Q4'...
Redeye has interviewed Smart Eye’s CEO, Martin Krantz, about the ongoing equity issue, the reason fo...
Redeye argues that the H2 report from Zwipe was largely in line with our expectations.
